Azenta Inc (AZTA)vsJohnson & Johnson (JNJ)
AZTA
Azenta Inc
$23.13
-4.58%
HEALTHCARE · Cap: $1.07B
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 16095% more annual revenue ($96.36B vs $595.03M). JNJ leads profitability with a 21.8% profit margin vs -10.1%. AZTA appears more attractively valued with a PEG of 0.53. JNJ earns a higher WallStSmart Score of 59/100 (C).
AZTA
Buy57
out of 100
Grade: C
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+42.6%
Fair Value
$53.08
Current Price
$23.13
$29.95 discount
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Earnings expanding 8778.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
0.8% revenue growth
Smaller company, higher risk/reward
ROE of 1.5% — below average capital efficiency
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZTA
The strongest argument for AZTA centers on Price/Book, EPS Growth, Debt/Equity. PEG of 0.53 suggests the stock is reasonably priced for its growth.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : AZTA
The primary concerns for AZTA are P/E Ratio, Revenue Growth, Market Cap.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
AZTA profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.
AZTA carries more volatility with a beta of 1.47 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 57/100), backed by strong 21.8% margins. AZTA offers better value entry with a 42.6% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Azenta Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Azenta Inc. is a premier provider of sample management solutions and life science tools, dedicated to enhancing laboratory efficiencies for the biotechnology and pharmaceutical industries. By leveraging innovative automated solutions, comprehensive biorepository services, and advanced storage technologies, the company enables clients to accelerate drug discovery while adhering to stringent regulatory requirements. With a strong emphasis on cutting-edge technology and strategic partnerships, Azenta is well-positioned to seize growth opportunities in the expanding global life sciences market. Its commitment to advancing scientific research through sophisticated products further solidifies its competitive advantage in biobanking and sample management.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?